3D MEDICINES (01244) to Partner with Kaituo Bio on tLNP Delivery and In Vivo CAR-T/NK Therapy Development

Stock News2025-08-20

3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, leveraging 3D MEDICINES' proprietary AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP), combined with Kaituo Bio's advantages and experience in large-scale mRNA production. Specific implementation will be formalized through subsequent formal agreements.

This partnership marks 3D MEDICINES' accelerated expansion into mRNA research, providing solid production capacity support for future clinical development and commercialization of innovative therapeutic products based on mRNA-LNP technology.

3D MEDICINES has established mRNA technology platforms and LNP delivery system platforms with global proprietary intellectual property rights. The mRNA technology platform is a multi-module tumor vaccine analysis platform (3D-PreciseAg) built on advanced AI technology, capable of supporting massive antigen multi-omics analysis and optimization of tumor antigens.

The company also possesses a proprietary AI-enhanced LNP delivery technology platform that can screen thousands of compounds through AI intelligent algorithms to synthesize various LNP products covering different delivery scenarios. This enhances the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK immunocell therapies while significantly reducing toxicity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101274232?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101274232","market":"nz","top_or_hot":-1,"title":"3D MEDICINES (01244) to Partner with Kaituo Bio on tLNP Delivery and In Vivo CAR-T/NK Therapy Development","media":"Stock News","content":"<p>3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, leveraging 3D MEDICINES' proprietary AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP), combined with Kaituo Bio's advantages and experience in large-scale mRNA production. Specific implementation will be formalized through subsequent formal agreements.</p>\n<p>This partnership marks 3D MEDICINES' accelerated expansion into mRNA research, providing solid production capacity support for future clinical development and commercialization of innovative therapeutic products based on mRNA-LNP technology.</p>\n<p>3D MEDICINES has established mRNA technology platforms and LNP delivery system platforms with global proprietary intellectual property rights. The mRNA technology platform is a multi-module tumor vaccine analysis platform (3D-PreciseAg) built on advanced AI technology, capable of supporting massive antigen multi-omics analysis and optimization of tumor antigens.</p>\n<p>The company also possesses a proprietary AI-enhanced LNP delivery technology platform that can screen thousands of compounds through AI intelligent algorithms to synthesize various LNP products covering different delivery scenarios. This enhances the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK immunocell therapies while significantly reducing toxicity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3D MEDICINES (01244) to Partner with Kaituo Bio on tLNP Delivery and In Vivo CAR-T/NK Therapy Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3D MEDICINES (01244) to Partner with Kaituo Bio on tLNP Delivery and In Vivo CAR-T/NK Therapy Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-20 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, leveraging 3D MEDICINES' proprietary AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP), combined with Kaituo Bio's advantages and experience in large-scale mRNA production. Specific implementation will be formalized through subsequent formal agreements.</p>\n<p>This partnership marks 3D MEDICINES' accelerated expansion into mRNA research, providing solid production capacity support for future clinical development and commercialization of innovative therapeutic products based on mRNA-LNP technology.</p>\n<p>3D MEDICINES has established mRNA technology platforms and LNP delivery system platforms with global proprietary intellectual property rights. The mRNA technology platform is a multi-module tumor vaccine analysis platform (3D-PreciseAg) built on advanced AI technology, capable of supporting massive antigen multi-omics analysis and optimization of tumor antigens.</p>\n<p>The company also possesses a proprietary AI-enhanced LNP delivery technology platform that can screen thousands of compounds through AI intelligent algorithms to synthesize various LNP products covering different delivery scenarios. This enhances the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK immunocell therapies while significantly reducing toxicity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAR","symbol_name":"安飞士","start_time":0,"source_url":"","article_id":"1101274232","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101274232","pubTimestamp":1755701542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAR":"安飞士","01244":"思路迪医药股份","BK1161":"生物科技","BK4022":"陆运","BK4230":"旅客陆运"},"translate_title":"3D MEDICINES(01244)将与开拓生物合作进行tLNP递送及体内CAR-T/NK疗法开发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1,"CAR":1},"content_text":"3D MEDICINES (01244) announced that the company entered into a strategic cooperation framework agreement with Kaituo Bio on August 20, 2025. Under this agreement, both parties will collaborate in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, leveraging 3D MEDICINES' proprietary AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP), combined with Kaituo Bio's advantages and experience in large-scale mRNA production. Specific implementation will be formalized through subsequent formal agreements.\nThis partnership marks 3D MEDICINES' accelerated expansion into mRNA research, providing solid production capacity support for future clinical development and commercialization of innovative therapeutic products based on mRNA-LNP technology.\n3D MEDICINES has established mRNA technology platforms and LNP delivery system platforms with global proprietary intellectual property rights. The mRNA technology platform is a multi-module tumor vaccine analysis platform (3D-PreciseAg) built on advanced AI technology, capable of supporting massive antigen multi-omics analysis and optimization of tumor antigens.\nThe company also possesses a proprietary AI-enhanced LNP delivery technology platform that can screen thousands of compounds through AI intelligent algorithms to synthesize various LNP products covering different delivery scenarios. This enhances the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK immunocell therapies while significantly reducing toxicity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101274232","isCrawlerRequest":true}